201 related articles for article (PubMed ID: 31389382)
1. Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: Are Indian patients different?
Sharma A; Vanidassane I; Aggarwal A; Mridha AR; Pandey R; Dhamija E; Barwad A; Rastogi S
Indian J Cancer; 2019; 56(3):207-210. PubMed ID: 31389382
[TBL] [Abstract][Full Text] [Related]
2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
3. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Karch A; Koch A; Grünwald V
Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
[TBL] [Abstract][Full Text] [Related]
7. Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials.
Vos M; Sleijfer S; Litière S; Touati N; Duffaud F; van der Graaf WT; Gelderblom H
Acta Oncol; 2019 Jun; 58(6):872-879. PubMed ID: 30831041
[No Abstract] [Full Text] [Related]
8. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
[TBL] [Abstract][Full Text] [Related]
11. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
[No Abstract] [Full Text] [Related]
12. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
Huang PW; Chou WC; Shen WC; Hung CY; Huang KG; Su YL; Lu CH; Liu CT; Chang YS; Liau CT
Asia Pac J Clin Oncol; 2018 Aug; 14(4):353-360. PubMed ID: 29900662
[TBL] [Abstract][Full Text] [Related]
13. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
Karaağaç M; Sezgin Y; Eryılmaz MK; Araz M; Kaplan MA; Artaç M
J Oncol Pharm Pract; 2020 Oct; 26(7):1657-1666. PubMed ID: 32063110
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F
Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
van der Graaf WT; Blay JY; Chawla SP; Kim DW; Bui-Nguyen B; Casali PG; Schöffski P; Aglietta M; Staddon AP; Beppu Y; Le Cesne A; Gelderblom H; Judson IR; Araki N; Ouali M; Marreaud S; Hodge R; Dewji MR; Coens C; Demetri GD; Fletcher CD; Dei Tos AP; Hohenberger P; ;
Lancet; 2012 May; 379(9829):1879-86. PubMed ID: 22595799
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan.
Teshima Y; Nomura S; Fukasawa N
Jpn J Clin Oncol; 2021 Apr; 51(4):612-621. PubMed ID: 33283234
[TBL] [Abstract][Full Text] [Related]
18. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
[TBL] [Abstract][Full Text] [Related]
19. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
[TBL] [Abstract][Full Text] [Related]
20. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
